LPL Financial’s Astria Therapeutics ATXS Stock Holding History

LPL Financial’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-167	Closed	-$8K	–	3077
2018 Q3	$8K	Buy	+167	New	+$7.5K	﹤0.01%	3217

Other funds holding ATXS

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

LPL Financial's ATXS Position: Q4 2018 in Review

LPL Financial sold out of Astria Therapeutics (ATXS) in Q4 2018, closing a stake of 167 shares — an estimated $8K sold.

LPL Financial first reported a position in ATXS in Q3 2018 and held it in 1 quarter. The position peaked at $8K in Q3 2018. 23 funds tracked by Wall St. Rank hold ATXS as of Q4 2018.

LPL Financial reported no remaining Astria Therapeutics position as of Q4 2018 after selling out during the quarter.
LPL Financial sold 167 Astria Therapeutics shares in Q4 2018, an estimated $8K.
LPL Financial first reported a position in Astria Therapeutics in Q3 2018 and held it in 1 quarter.
LPL Financial's Astria Therapeutics position peaked at $8K in Q3 2018.
23 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2018.

Based on LPL Financial's 13F filing for Q4 2018, filed 7 Feb 2019.